{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:52:12Z","timestamp":1794027132071,"version":"4.8.0"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001287","name":"Elsa U. Pardee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006928","name":"Ohio State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Natural killer group 2 D (NKG2D) receptor, one of the activation receptors on NK cells, has gained increasing attention in recent years because its ligands are widely expressed in most cancers. Naturally, NKG2D reacts to 8 different stress-induced ligands, MICA\/B, and ULBP1-6. Despite being genomically conserved between human and mouse, NKG2D transcripts have splice variants that can differentiate the two. hNKG2D or mNKG2D (both long and short transcripts) interacts with DAP10 only in human but DAP10\/12 in mouse, switching on different effector functions such as IFN-\u03b3 production and cytotoxicity. Full-length, extracellular or cytoplasmic domains have been used to construct chimeric antigen receptors (CAR) or implement into the antibody structures including bispecific antibodies. Interestingly, most of the NKG2D CARs, either on T cells or NK cells are investigated in preclinical models of solid tumors. In this article, we reviewed the majority of published NKG2D-based CAR and antibody designs, comparing their respective advantages and disadvantages. We also elaborated how these CARs and antibodies were tested in preclinical cancer models and clinical trials in this review article.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1557644","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:12:20Z","timestamp":1750306340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Designs of NKG2D-based immunotherapeutics for cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jianfeng","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey Chi-Fung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Keung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258867","article-title":"Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection","volume":"348","author":"Deng","year":"2015","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1199","article-title":"Roles of the NKG2D immunoreceptor and its ligands","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2013.17","article-title":"NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors","volume":"91","author":"Spear","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"B4","first-page":"8","article-title":"NKG2D ligands as therapeutic targets","volume":"13","author":"Spear","year":"2013","journal-title":"Cancer Immun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0098","article-title":"NKG2D receptor and its ligands in host defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1351","article-title":"Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion","volume":"107","author":"Bryceson","year":"2006","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2008.02.004","article-title":"The NKG2D receptor: sensing stressed cells","volume":"14","author":"L\u00f3pez-Larrea","year":"2008","journal-title":"Trends Mol Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ni1325","article-title":"NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells","volume":"7","author":"Upshaw","year":"2006","journal-title":"Nat Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5428.730","article-title":"An activating immunoreceptor complex formed by NKG2D and DAP10","volume":"285","author":"Wu","year":"1999","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00827","article-title":"The NKG2D\/NKG2DL axis in the crosstalk between lymphoid and myeloid cells in health and disease","volume":"9","author":"Stojanovic","year":"2018","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2013.111","article-title":"Advances in NKG2D ligand recognition and responses by NK cells","volume":"92","author":"Le Bert","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab018","article-title":"A summary of current NKG2D-based CAR clinical trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000029","article-title":"NKG2D CARs as cell therapy for cancer","volume":"20","author":"Sentman","year":"2014","journal-title":"Cancer J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902000","article-title":"Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment","volume":"183","author":"Barber","year":"2009","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580328","article-title":"Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"11","author":"Driouk","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2251","article-title":"Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.119","article-title":"T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice","volume":"23","author":"VanSeggelen","year":"2015","journal-title":"Mol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.893124","article-title":"Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells","volume":"12","author":"Wei","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.72","article-title":"Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer","volume":"180","author":"Barber","year":"2008","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/cancers12071969","article-title":"Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion","volume":"12","author":"He","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03247-9","article-title":"Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis","volume":"72","author":"Jiang","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23564","article-title":"Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors","volume":"2","author":"Spear","year":"2013","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0026","article-title":"Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3670-0","article-title":"Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment","volume":"82","author":"Tao","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863346","article-title":"Orthotopic and heterotopic murine models of pancreatic cancer exhibit different immunological microenvironments and different responses to immunotherapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110562","article-title":"Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer","volume":"131","author":"Zhang","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/hum.2012.143","article-title":"Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition","volume":"24","author":"Song","year":"2013","journal-title":"Hum Gene Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the","volume":"23","author":"Du","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41389-021-00353-8","article-title":"Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway","volume":"10","author":"Gao","year":"2021","journal-title":"Oncogenesis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2023.01.010","article-title":"Engagement of an optimized lentiviral vector enhances the expression and cytotoxicity of CAR in human NK cells","volume":"155","author":"Guo","year":"2023","journal-title":"Mol Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s42003-020-1021-2","article-title":"convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting","volume":"3","author":"Landgraf","year":"2020","journal-title":"Commun Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2022.0415","article-title":"A soluble NK-CAR mediates the specific cytotoxicity of NK cells toward the target CD20","volume":"13","author":"Liu","year":"2022","journal-title":"Aging Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2020.08.016","article-title":"T cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication","volume":"29","author":"Ng","year":"2021","journal-title":"Mol Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.02.023","article-title":"Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells","volume":"21","author":"Tay","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20460","article-title":"Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro","volume":"9","author":"Zarei","year":"2023","journal-title":"Heliyon"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15828","article-title":"Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer","volume":"114","author":"Zhang","year":"2023","journal-title":"Cancer Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115740","article-title":"Co-expression of IL-4\/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment","volume":"168","author":"Zhou","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0075","article-title":"Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells","volume":"23","author":"Fern\u00e1ndez","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","article-title":"Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells","volume":"11","author":"Han","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2023.0043","article-title":"Annihilation of non-small cell lung cancer by NKG2D CAR-T cells produced from T cells from peripheral blood of healthy donors","volume":"43","author":"Jiang","year":"2023","journal-title":"J Interferon Cytokine Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031210","article-title":"Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection","volume":"7","author":"Lehner","year":"2012","journal-title":"PloS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-018-0441-8","article-title":"Purinergic targeting enhances immunotherapy of CD73","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40425-019-0642-9","article-title":"T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells","volume":"7","author":"Yang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e002980","DOI":"10.1136\/jitc-2021-002980","article-title":"Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity","volume":"9","author":"Zhang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106443","article-title":"CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid Malignancies","volume":"26","author":"Trinh","year":"2023","journal-title":"iScience"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12634","article-title":"T cells engineered with full-length NKG2D linked to signaling domains of 4-1BB and CD3\u03b6 show enhanced antitumor activity","volume":"101","author":"Teng","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.04.013","article-title":"Electroporation of NKG2D RNA CAR improves V\u03b39V\u03b42 T cell responses against human solid tumor xenografts","volume":"17","author":"Ang","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.07.009","article-title":"Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells","volume":"114","author":"Guo","year":"2019","journal-title":"Mol Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2020.04.016","article-title":"A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis","volume":"122","author":"Lu","year":"2020","journal-title":"Mol Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4384","article-title":"Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma","volume":"28","author":"Meister","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res"},{"key":"B57","article-title":"Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo","volume":"9","author":"Deng","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2057490","article-title":"Infusion of haploidentical NKG2D-CAR-T","volume":"63","author":"Fern\u00e1ndez","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1187665","article-title":"NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia","volume":"14","author":"Ib\u00e1\u00f1ez-Navarro","year":"2023","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2248826","article-title":"CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells","volume":"12","author":"Jin","year":"2023","journal-title":"Oncoimmunology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J"},{"key":"B62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-022-01541-9","article-title":"A novel approach for relapsed\/refractory FLT3","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1509173","article-title":"DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells","volume":"8","author":"Zhao","year":"2019","journal-title":"Oncoimmunology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1002361","article-title":"Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017075","article-title":"Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types","volume":"7","author":"Lonez","year":"2017","journal-title":"BMJ Open"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04865-1","article-title":"T cells with split CARs specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo","volume":"149","author":"Sun","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12321","article-title":"The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death","volume":"42","author":"Wu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0137","article-title":"Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR","volume":"12","author":"Li","year":"2020","journal-title":"Immunotherapy"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00720.x","article-title":"DAP10- and DAP12-associated receptors in innate immunity","volume":"227","author":"Lanier","year":"2009","journal-title":"Immunol Rev"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/80877","article-title":"CD27 is required for generation and long-term maintenance of T cell immunity","volume":"1","author":"Hendriks","year":"2000","journal-title":"Nat Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12885-023-11806-1","article-title":"Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1187665","article-title":"NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells","volume":"14","author":"Ibanez-Navarro","year":"2023","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add1951","article-title":"NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates","volume":"15","author":"Yang","year":"2023","journal-title":"Sci Transl Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells","volume":"23","author":"Du","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B75","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-018-0441-8","article-title":"Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0572","article-title":"NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors","volume":"7","author":"Parihar","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.04.013","article-title":"Electroporation of NKG2D RNA CAR improves vgamma9Vdelta2 T cell responses against human solid tumor xenografts","volume":"17","author":"Ang","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3171\/2014.9.JNS132253","article-title":"Stem cell signature in glioblastoma: therapeutic development for a moving target","volume":"122","author":"Nakano","year":"2015","journal-title":"J Neurosurg"},{"key":"B79","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/biom12030358","article-title":"Anti-GD2 directed immunotherapy for high-risk and metastatic neuroblastoma","volume":"12","author":"Chan","year":"2022","journal-title":"Biomolecules"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1316439","article-title":"MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma","volume":"6","author":"Brandetti","year":"2017","journal-title":"Oncoimmunology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00747-0","article-title":"Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention","volume":"20","author":"Thrift","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.078170","article-title":"Protein 4.1R regulates cell adhesion, spreading, migration and motility of mouse keratinocytes by modulating surface expression of beta1 integrin","volume":"124","author":"Chen","year":"2011","journal-title":"J Cell Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13578-023-01005-7","article-title":"GPR116 receptor regulates the antitumor function of NK cells via G\u03b1q\/HIF1\u03b1\/NF-\u03baB signaling pathway as a potential immune checkpoint","volume":"13","author":"Guo","year":"2023","journal-title":"Cell Biosci"},{"key":"B84","first-page":"199","volume-title":"World cancer report 2020","author":"Wild","year":"2020"},{"key":"B85","doi-asserted-by":"publisher","first-page":"107952","DOI":"10.1016\/j.isci.2023.107952","article-title":"Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design","volume":"26","author":"Li","year":"2023","journal-title":"iScience"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111299","article-title":"Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia","volume":"137","author":"Wu","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00957","article-title":"Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing","volume":"10","author":"Ingegnere","year":"2019","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0613-7","article-title":"Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia","volume":"34","author":"Quintarelli","year":"2020","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020023","article-title":"Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL","volume":"142","author":"Del Bufalo","year":"2023","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2018.03.001","article-title":"Celyad's novel CAR T-cell therapy for solid Malignancies","volume":"66","author":"Lonez","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000413","article-title":"Clinical grade manufacture of CYAD-101, a NKG2D-based, first in class, non-gene-edited allogeneic CAR T-cell therapy","volume":"45","author":"Michaux","year":"2022","journal-title":"J Immunother"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0232","article-title":"232 NKG2D-based multi-specific CAR T-cells to overcome antigen escape and improve anti-tumor efficacy","volume":"11","author":"Bols\u00e9e","year":"2023","journal-title":"J ImmunoTherapy Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.40","article-title":"Tandem CAR-T cells targeting CLDN18.2 and NKG2DL for treatment of gastric cancer","volume":"40","author":"Hui","year":"2023","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2057490","article-title":"Infusion of haploidentical NKG2D-CAR-T(CD45RA-) cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits","volume":"63","author":"Fernandez","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129998","article-title":"Next Generation NKG2D-based CAR T-cells (CYAD-02): Co-expression of a Single shRNA Targeting MICA and MICB Improves Cell Persistence and Anti-Tumor Efficacy in vivo","volume":"134","author":"Fontaine","year":"2019","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3667","article-title":"Costimulation of multiple NK cell activation receptors by NKG2D","volume":"169","author":"Ho","year":"2002","journal-title":"J Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201243150","article-title":"NKG2D regulates production of soluble TRAIL by ex vivo expanded human \u03b3\u03b4 T cells","volume":"43","author":"Dokouhaki","year":"2013","journal-title":"Eur J Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12517","article-title":"The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells","volume":"54","author":"Talebian","year":"2014","journal-title":"Transfusion"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001248","article-title":"Oxaliplatin facilitates tumor-infiltration of T cells and natural-killer cells for enhanced tumor immunotherapy in lung cancer model","volume":"33","author":"Xin","year":"2022","journal-title":"Anticancer Drugs"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.74","article-title":"The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia","volume":"24","author":"N\u00fcckel","year":"2010","journal-title":"Leukemia"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711293105","article-title":"MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-370841","article-title":"High ERp5\/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas","volume":"119","author":"Zocchi","year":"2012","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3892\/ol.2023.13883","article-title":"Soluble NKG2D ligands impair CD8","volume":"26","author":"Zhang","year":"2023","journal-title":"Oncol Lett"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1123367","article-title":"ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing","volume":"5","author":"Zocchi","year":"2016","journal-title":"Oncoimmunology"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0313","article-title":"Nutlin-3a enhances natural killer cell-mediated killing of neuroblastoma by restoring p53-dependent expression of ligands for NKG2D and DNAM-1 receptors","volume":"9","author":"Veneziani","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886319","article-title":"DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells","volume":"13","author":"Focaccetti","year":"2022","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"VIII420","DOI":"10.1093\/annonc\/mdy288.051","article-title":"Tackling fratricide to manufacture clinical grade NKG2D-CAR T cells for cancer therapy","volume":"8","author":"Demoulin","year":"2018","journal-title":"Immunotherapy Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/sj.bjp.0706061","article-title":"LY294002 and rapamycin co-operate to inhibit T-cell proliferation","volume":"144","author":"Breslin","year":"2005","journal-title":"Br J Pharmacol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1009089","article-title":"Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303605","article-title":"NK cell exhaustion in the tumor microenvironment","volume":"14","author":"Jia","year":"2023","journal-title":"Front Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1854529","article-title":"Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response","volume":"10","author":"Raynaud","year":"2020","journal-title":"Oncoimmunology"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1227572","article-title":"Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of Malignant B cells by NK cells and T cells","volume":"14","author":"Lutz","year":"2023","journal-title":"Front Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2433121","article-title":"Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands","volume":"16","author":"Fallon","year":"2024","journal-title":"MAbs"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2008.09.008","article-title":"Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity","volume":"384","author":"Kwong","year":"2008","journal-title":"J Mol Biol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324705","article-title":"Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors","volume":"34","author":"Andr\u00e9","year":"2004","journal-title":"Eur J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1557644\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:12:22Z","timestamp":1750306342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1557644\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":117,"alternative-id":["10.3389\/fimmu.2025.1557644"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1557644","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"article-number":"1557644"}}